Status:
UNKNOWN
Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis
Lead Sponsor:
Universidad de Antioquia
Collaborating Sponsors:
Hospital Pablo Tobón Uribe
Conditions:
Pharmacological Action
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The pharmacogenomics of the Colombian population with rheumatoid arthritis (RA), understood as the individual response to drugs depending on the genome of each patient, can be an explanation for the p...
Detailed Description
Rheumatoid arthritis is an important public health problem; In recent years better health outcomes have been achieved with the incorporation of synthetic and biological disease modifying drugs. Howeve...
Eligibility Criteria
Inclusion
- Patients with rheumatoid arthritis on treatment with Methotrexate, Adalimumab, Infliximab or Etanercept (monotherapy or combination therapy)
- Over 18 years
- With DAS 28 (Disease Activity Score in 28 Joints) greater than 3.2
- With SDAI (Simple Disease Activity Index) less than 3.3
- Use of medication\> 3 months
- Anti TNFα, used for the first time.
- Subscribe to informed consent
Exclusion
- Patients who after applying the tool to identify other causes of variability; Identify other causes that variability in response (non-adherence to travel, forgetfulness, etc.).
- Previous use of anti TNFα drugs.
- Inpatient Patients
Key Trial Info
Start Date :
October 17 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 17 2020
Estimated Enrollment :
372 Patients enrolled
Trial Details
Trial ID
NCT03352622
Start Date
October 17 2017
End Date
September 17 2020
Last Update
February 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pablo Tobon Uribe Hospital
Medellín, Colombia